China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a pre-IPO financing round. The funding was led by Gree Financial Investment and KingRay Capital, with additional participation from Efung Capital, China Medical System Holdings (CMS; HKG: 0867), Wuxi Guolian Development (Group), and other investors.
Technology and Pipeline
Trinomab applies its integrated natural human monoclonal antibody (mAb) research and development technology platform, HitmAb, to develop whole human mAbs. The company boasts a robust product pipeline consisting of nearly 20 antibodies, including 5 in-house discoveries that have entered or are nearing clinical stages, 2 in-licensed products, and 3 products developed in partnership with others. Among these, TNM002, the world’s first tetanus mAb to reach Phase III, has obtained breakthrough therapy designation in China and fast-track status in the US. Additionally, TNM001 is the first home-grown RSV mAb.-Fineline Info & Tech
